Large Molecule

Bristol-Myers Squibb Acquires License from Novo Nordisk

Mar 24, 2015

Bristol-Myers Squibb Company signed an agreement with Novo Nordisk under which BMS will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases, according to a press release. Terms of the agreement were not announced.

Bristol-Myers Squibb says the agreement supports its long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.

Read the full release